We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vac... Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.15 | 7.5 | 2 | 2.32 | 1.71 | 320455 | 1.87141443 | CS |
4 | -0.15 | -6.52173913043 | 2.3 | 2.53 | 1.71 | 301690 | 2.06089274 | CS |
12 | -2.01 | -48.3173076923 | 4.16 | 5.75 | 1.71 | 286434 | 2.84865347 | CS |
26 | -11.77 | -84.5545977011 | 13.92 | 14.74 | 1.71 | 197449 | 4.48560907 | CS |
52 | -30.91 | -93.4966727163 | 33.06 | 35.15 | 1.71 | 183199 | 11.84693199 | CS |
156 | -3.85 | -64.1666666667 | 6 | 40.98 | 1.71 | 154261 | 13.64293877 | CS |
260 | -3.85 | -64.1666666667 | 6 | 40.98 | 1.71 | 154261 | 13.64293877 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions